A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

Learn more Eli Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter ...

Integrating with Lilly’s Employer Connect allows Omada to provide another option with transparent net cost for Zepbound ® and enables defined contribution levels from employers, creating a predictable ...

Eli Lilly shares jumped after the drugmaker posted earnings that topped estimates and hiked its outlook, thanks to booming ...

About 1 in 8 Americans have used GLP-1s for weight loss — but more than three-quarters quit taking them within two years.

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy innovation supports long-term health.

Lilly heads into Q1 earnings with GLP-1 drugs driving growth. However, pricing pressure, rising costs, and softer Foundayo ...

GLP-1 use isn't just drastically changing the lives of those, like McDonald, who are on the weight-loss drug. It's changing ...

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the ...

Obesity drug giant Eli Lilly on Thursday reported a monster first quarter, fortifying our conviction to stick with the stock ...

Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these ...

Oba Femi walked out to what felt like a ticker tape championship celebration. Fans wouldn’t let him speak for minutes, chanting “Oba” and “Oba Femi!" “The ruler has arrived!” said Oba Femi before ...